Biostar Pharmaceuticals, Inc. (BSPM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biostar Pharmaceuticals, Inc. (BSPM) with AI Score 47/100 (Weak). Biostar Pharmaceuticals, Inc. focuses on developing, manufacturing, and marketing pharmaceutical products in China. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Biostar Pharmaceuticals, Inc. (BSPM) Healthcare & Pipeline Overview
Biostar Pharmaceuticals, Inc., based in China, develops and markets OTC and prescription pharmaceutical products, including its key product Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products across 28 provinces in China, leveraging both distributors and a direct sales network.
Investment Thesis
Biostar Pharmaceuticals operates in the Chinese pharmaceutical market, focusing on both OTC and prescription drugs. The company's key product, Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B, addresses a significant health issue in China. However, with a negative profit margin of -239.0% and a market capitalization of $0.00B, the company faces significant financial challenges. Potential growth catalysts include expanding its product line and increasing its market penetration within China. Investors should carefully consider the risks associated with investing in OTC-listed companies, including liquidity and disclosure concerns.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 38.4% indicates potential for profitability if costs are managed effectively.
- Operates in 28 provinces in China, demonstrating a significant distribution network.
- Offers both OTC and prescription drugs, diversifying its revenue streams.
- Key product, Xin Ao Xing Oleanolic Acid capsule, targets chronic hepatitis B, a significant health issue in China.
- Profit Margin of -239.0% signals financial challenges requiring strategic intervention.
Competitors & Peers
Strengths
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
Weaknesses
- Negative profit margin.
- Limited financial resources.
- Dependence on a single key product (Xin Ao Xing).
- OTC listing indicates higher risk.
Catalysts
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
- Ongoing: Expansion of the company's distribution network in China.
- Ongoing: Increased adoption of the China Hepatitis Internet hospital platform.
Risks
- Potential: Competition from larger pharmaceutical companies.
- Potential: Regulatory changes in China.
- Ongoing: Fluctuations in raw material prices.
- Ongoing: Economic slowdown in China.
- Ongoing: Negative profit margin and limited financial resources.
Growth Opportunities
- Expanding its OTC product line: Biostar can capitalize on the growing demand for OTC medications in China by introducing new products targeting common ailments. The Chinese OTC market is projected to reach $50 billion by 2028, offering significant revenue potential. Timeline: Launching 2-3 new OTC products annually over the next 3-5 years could significantly boost revenue.
- Increasing market penetration in existing provinces: Biostar currently operates in 28 provinces in China. Deepening its market penetration within these regions through targeted marketing and sales initiatives can drive revenue growth. The pharmaceutical market in these provinces is estimated at $200 billion, offering ample opportunity for expansion. Timeline: Achieving a 1% increase in market share in each province over the next 2 years.
- Leveraging its online platform: Biostar's China Hepatitis Internet hospital provides a direct channel to reach HBV patients. Expanding the platform's services and offerings, such as online consultations and prescription refills, can enhance customer engagement and drive sales. The online healthcare market in China is projected to reach $40 billion by 2027. Timeline: Expanding online services and increasing user engagement by 20% annually.
- Developing new prescription drugs: Biostar can invest in research and development to create new prescription drugs targeting unmet medical needs in China. The prescription drug market in China is projected to reach $300 billion by 2028. Timeline: Launching 1-2 new prescription drugs every 3 years.
- Strategic partnerships and acquisitions: Biostar can explore strategic partnerships or acquisitions to expand its product portfolio, market reach, and technological capabilities. The Chinese pharmaceutical market is consolidating, presenting opportunities for strategic alliances. Timeline: Pursuing 1-2 strategic partnerships or acquisitions over the next 5 years.
Opportunities
- Expanding OTC product line.
- Increasing market penetration in existing provinces.
- Leveraging online platform for growth.
- Developing new prescription drugs.
Threats
- Competition from larger pharmaceutical companies.
- Regulatory changes in China.
- Fluctuations in raw material prices.
- Economic slowdown in China.
Competitive Advantages
- Established distribution network in 28 provinces in China.
- Focus on traditional Chinese medicine.
- Key product targeting chronic hepatitis B, a significant health issue in China.
- Online platform providing direct access to HBV patients.
About BSPM
Biostar Pharmaceuticals, Inc., established in 2007 and headquartered in Xianyang, China, is engaged in the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes both over-the-counter (OTC) and prescription medications, addressing a variety of diseases and conditions prevalent in the Chinese market. Its primary product is Xin Ao Xing Oleanolic Acid capsule, an OTC medicine indicated for chronic hepatitis B, a significant health concern in China. In addition to Xin Ao Xing, Biostar offers 12 other OTC products and 17 prescription-based pharmaceuticals, catering to a broad spectrum of healthcare needs. Biostar's OTC product line includes Ganwang compound paracetamol and amantadine hydrochloride capsule for cold and flu symptoms, Tianqi Dysmenorrhea capsule for menstrual pain, Deafness Tongqiao pills for ear-related issues, Wenweishu capsules for chronic gastritis, Zhitongtougu ointment for joint pain, and Chuzhang Zehaifu tablets for cataract. The company's prescription drugs cover areas such as cardiovascular health (Danshen granules and tablets), pediatric care (Taohuasan), and various other conditions including rhinitis, hyperthyroidism, and bacterial infections. Biostar also operates an online platform, the China Hepatitis Internet hospital, providing information and treatment options for HBV patients, as well as facilitating the purchase of HBV medicines. The company distributes its products through a network of distributors and sales personnel, reaching approximately 28 provinces across China.
What They Do
- Develops over-the-counter (OTC) pharmaceutical products.
- Manufactures prescription pharmaceutical products.
- Markets pharmaceutical products for various diseases and conditions.
- Offers Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
- Provides traditional Chinese medicines.
- Operates an online platform for HBV patients.
Business Model
- Develops and manufactures OTC and prescription pharmaceutical products.
- Sells products through distributors and a network of sales people in China.
- Operates an online platform (China Hepatitis Internet hospital) for HBV patients.
- Generates revenue from the sale of pharmaceutical products.
Industry Context
Biostar Pharmaceuticals operates within the Chinese pharmaceutical market, a large and rapidly growing sector driven by increasing healthcare expenditure and an aging population. The market is characterized by a mix of domestic and international players, with a growing demand for both OTC and prescription drugs. Biostar competes with other generic drug manufacturers, including BIOCQ, CLVR, CRFTF, CWWBF, and ELOX, as well as larger multinational pharmaceutical companies. The company's focus on traditional Chinese medicine and its established distribution network provide a competitive advantage in certain segments of the market.
Key Customers
- Patients in China seeking OTC medications for common ailments.
- Patients in China requiring prescription medications for various diseases.
- Hospitals and clinics in China that purchase pharmaceutical products.
- Distributors who sell Biostar's products to pharmacies and other retailers.
Financials
Chart & Info
Biostar Pharmaceuticals, Inc. (BSPM) stock price: Price data unavailable
Latest News
No recent news available for BSPM.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSPM.
Price Targets
Wall Street price target analysis for BSPM.
MoonshotScore
What does this score mean?
The MoonshotScore rates BSPM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Ronghua Wang
CEO
Ronghua Wang serves as the CEO of Biostar Pharmaceuticals, Inc. He is responsible for managing the company's overall operations and strategic direction. His background includes experience in the pharmaceutical industry, with a focus on sales and marketing. He has been instrumental in expanding the company's distribution network and product portfolio. He oversees a workforce of approximately 200 employees.
Track Record: Under Ronghua Wang's leadership, Biostar Pharmaceuticals has focused on developing and marketing pharmaceutical products in China. Key milestones include the expansion of the company's OTC product line and the establishment of the China Hepatitis Internet hospital. However, the company's financial performance, as indicated by its negative profit margin, remains a challenge.
BSPM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biostar Pharmaceuticals may not meet the listing requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
BSPM Healthcare Stock FAQ
What does Biostar Pharmaceuticals, Inc. do?
Biostar Pharmaceuticals, Inc. is a Chinese pharmaceutical company that develops, manufactures, and markets both over-the-counter (OTC) and prescription drugs. Its primary focus is on addressing common diseases and conditions in China, with a key product being Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products through a network of distributors and sales personnel, as well as through its online platform, the China Hepatitis Internet hospital, reaching patients across 28 provinces in China.
What do analysts say about BSPM stock?
AI analysis is currently pending for Biostar Pharmaceuticals, Inc. (BSPM). Given its OTC listing and negative profit margin, investors should conduct thorough due diligence and carefully assess the risks associated with investing in this company. Key valuation metrics, such as price-to-earnings ratio, are currently not meaningful due to the company's lack of profitability. Growth considerations include the potential for expanding its product line and increasing its market penetration within China.
What are the main risks for BSPM?
The main risks for Biostar Pharmaceuticals, Inc. include its negative profit margin, limited financial resources, and dependence on a single key product. As an OTC-listed company, BSPM faces additional risks related to liquidity, disclosure, and regulatory oversight. Competition from larger pharmaceutical companies and regulatory changes in China also pose significant challenges. Investors should carefully consider these risks before investing in BSPM.
What are the key factors to evaluate for BSPM?
Biostar Pharmaceuticals, Inc. (BSPM) currently holds an AI score of 47/100, indicating low score. Key strength: Established distribution network in China.. Primary risk to monitor: Potential: Competition from larger pharmaceutical companies.. This is not financial advice.
How frequently does BSPM data refresh on this page?
BSPM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BSPM's recent stock price performance?
Recent price movement in Biostar Pharmaceuticals, Inc. (BSPM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established distribution network in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BSPM overvalued or undervalued right now?
Determining whether Biostar Pharmaceuticals, Inc. (BSPM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BSPM?
Before investing in Biostar Pharmaceuticals, Inc. (BSPM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC stocks carry higher risks than exchange-listed stocks.